These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3932716)

  • 21. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 22. Induced immunotolerance in factor VIII inhibitor patients.
    Brackmann HH
    Prog Clin Biol Res; 1984; 150():181-95. PubMed ID: 6431426
    [No Abstract]   [Full Text] [Related]  

  • 23. Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A.
    Sullivan DW; Purdy LJ; Billingham M; Glader BE
    Pediatrics; 1984 Aug; 74(2):279-81. PubMed ID: 6431390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract]   [Full Text] [Related]  

  • 25. Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia A patients with factor VIII inhibitor.
    Sugihara T; Takahashi I; Kojima T; Okamoto Y; Yamamoto K; Kamiya T; Matsushita T; Saito H
    Nagoya J Med Sci; 2000 May; 63(1-2):25-39. PubMed ID: 10911718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitor to factor VIII in mild haemophilia.
    Kesteven PJ; Holland LJ; Lawrie AS; Savidge GF
    Thromb Haemost; 1984 Aug; 52(1):50-2. PubMed ID: 6437010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 28. Current status and trends in the treatment of hemophilic patients with inhibitors.
    Bloom AL
    Prog Clin Biol Res; 1981; 72():123-38. PubMed ID: 6801682
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hemophilia A with inhibitor].
    Takahashi I
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):498-501. PubMed ID: 9833554
    [No Abstract]   [Full Text] [Related]  

  • 30. HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody.
    Frommel D; Allain JP; Saint-Paul E; Bosser C; Noël B; Mannucci PM; Pannicucci F; Blombäck M; Prou-Wartelle O; Muller JY
    Thromb Haemost; 1981 Dec; 46(4):687-9. PubMed ID: 6800049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Inhibitor hemophilia in oral surgery].
    Schulz S
    Zahn Mund Kieferheilkd Zentralbl; 1984; 72(8):824-8. PubMed ID: 6240865
    [No Abstract]   [Full Text] [Related]  

  • 32. [Incidence of the appearance of factor VIII inhibitor in patients with hemophilia A at the Hemophilia Center of the Clinical Hospital Center in Zagreb].
    Ficović P; Tiefenbach A; Brkljacić V; Grgić Z
    Lijec Vjesn; 1983 Oct; 105(10):410-1. PubMed ID: 6418997
    [No Abstract]   [Full Text] [Related]  

  • 33. [Inhibitors against factor VIII in hemophilia. A review of treatment possibilities and personal results].
    Scheibel E; Feddersen C
    Ugeskr Laeger; 1985 Nov; 147(47):3803-7. PubMed ID: 3934824
    [No Abstract]   [Full Text] [Related]  

  • 34. A case of factor VIII inhibitor-positive acquired hemophilia treated by plasmapheresis.
    Narukawa N; Abe T; Shouno M; Kitabata Y; Okamoto M; Kobata H; Akizawa T
    Ther Apher; 1999 Nov; 3(4):323-5. PubMed ID: 10608728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L; Bariska I; Marton E
    Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract]   [Full Text] [Related]  

  • 36. [Intraoperative use of plasma-derived activated factor VII (F VII a) in a hemophilia A patient with inhibitors].
    Matsuyama K; Ushijima K; Kano T; Tsuchiya H
    Masui; 1996 Feb; 45(2):235-8. PubMed ID: 8865715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates.
    Brettler DB
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):45-6. PubMed ID: 1908128
    [No Abstract]   [Full Text] [Related]  

  • 38. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-factor VIII anamnesis after factor IX complex.
    Palascak JE; Shapiro SR
    N Engl J Med; 1977 Dec; 297(25):1403. PubMed ID: 927458
    [No Abstract]   [Full Text] [Related]  

  • 40. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.